HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study
There was no significant difference in the risk of HBV reactivation between patients with HCC with HBV DNA ≤500 IU/mL and those with HBV DNA >500 IU/mL when treated with ICIs and concurrent antiviral prophylaxis.
Authors
- QiJiong Li (ORCID: https://orcid.org/0000-0002-3149-1645)
- MinKe He (ORCID: https://orcid.org/0009-0001-5832-0942)
- Anna Kan (ORCID: https://orcid.org/0000-0002-0405-6920)
- Yaojun Zhang (ORCID: https://orcid.org/0000-0002-9752-4729)
- Wei Wei (ORCID: https://orcid.org/0000-0003-0059-8447)
- ZhiCheng Lai (ORCID: https://orcid.org/0000-0003-4109-9468)
- ZeFeng Du (ORCID: https://orcid.org/0009-0008-6342-1888)
- Binkui Li (ORCID: https://orcid.org/0000-0003-3201-2914)
- Li Xu (ORCID: https://orcid.org/0000-0003-4405-1048)
- H. Chen (ORCID: https://orcid.org/0000-0001-9731-824X)
- YeXing Huang (ORCID: https://orcid.org/0009-0009-5453-6728)
- Ming Shi (ORCID: https://orcid.org/0000-0002-4051-4474)
- MinShan Chen (ORCID: https://orcid.org/0000-0002-7442-4637)
- Ping Ma (ORCID: https://orcid.org/0000-0001-5167-2702)
Institutions
- Sun Yat-sen University (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Twelfth Guangzhou City People's Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2859
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00